New York, March 10, 2023 - PRISM MarketView - Shares in innovative drug delivery platform company, Lexaria Bioscience (Nasdaq: LEXX), have been on the rise this week. The company is eyeing a slice of the booming obesity drug market which grew to an astonishing $90 billion in value in 2023, following the success of blockbuster GLP-1 drugs Ozempic® and Wegovy®.
According to Lexaria, an injection-free weight loss solution that doesn’t cause stomach upsets could be closer than we think. The company’s DehydraTECH drug delivery technology enables improved and more rapid absorption of drugs into the bloodstream and brain tissues. Lexaria has demonstrated in a number of studies that its DehydraTECH formulations begin to take effect in as little as 1.5 minutes after dosing, and that intestinal bioabsorption of bioactive compounds is increased by as much as 17x. The result is greater bioavailability of therapeutics at reduced doses.
Lexaria announced on Friday that it has engaged a contract research organization (CRO) to perform the company’s second DehydraTECH-powered GLP-1 human pilot study which will compare three dose formulations: DehydraTECH-semaglutide swallowed capsules, an in-mouth dissolvable DehydraTECH-semaglutide oral tablet, and a positive control Rybelsus® swallowed tablet.
“DehydraTECH has previously shown an ability to improve delivery of certain drugs destined for the bloodstream, through the buccal/sublingual tissues of the mouth and throat. If this new study is successful in demonstrating efficacy and safety, the potential for a new era in GLP-1 delivery without the need for painful injections or stomach-upsetting tablets, could be within reach.”
Chris Bunka, Lexaria’s CEO
This week, Lexaria also announced that it will examine diabetes and weight loss effects of DehydraTECH-processed GLP-1 drugs and DehydraTECH-processed cannabidiol, alone and in combination in a 12-week animal study. The company previously demonstrated weight loss of 7% and a statistically significant reduction of 19.9% in blood glucosein an eight week animal study.
Lexaria will also evaluate its DehydraTECH technology in the treatment of hypertension after it received FDA clearance of an investigational new drug (IND) application for a Phase 1b hypertension clinical trial. Lexaria has demonstrated significant reductions in resting blood pressure in five human clinical studies of DehydraTECH-CBD in healthy normal and hypertensive volunteers, suggesting that DehydraTECH-CBD has the potential to deliver pronounced clinical benefits relative to available anti-hypertensive therapeutics.
About Lexaria Bioscience Corp. & DehydraTECH
DehydraTECH™ is Lexaria’s patented drug delivery formulation and processing platform technology which improves the way active pharmaceutical ingredients (APIs) enter the bloodstream through oral delivery. Since 2016, Lexaria has developed and investigated DehydraTECH with a variety of beneficial molecules in oral and topical formats. DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption and has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier, which Lexaria believes to be of particular importance for centrally active compounds. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 39 patents granted and many patents pending worldwide. For more information, please visit www.lexariabioscience.com.
About PRISM MarketView:
Established in 2020, PRISM MarketView is dedicated to the monitoring and analysis of small cap stocks in burgeoning sectors. We deliver up-to-the-minute financial market news, provide comprehensive investor tools and foster a dynamic investor community. Central to our offerings are proprietary indexes that observe emerging sectors, including biotech, clean energy, next-generation tech, medical devices and beyond. Visit us at prismmarketview.com and follow us on Twitter.
Disclaimer:
PRISM MarketView is not a registered or licensed broker-dealer or investment adviser and does not offer investment advice. The information provided in this communication is not intended to constitute an offer to sell, a solicitation of an offer to buy, or a recommendation for any security.
Contact:
Prism MarketView | Stock Market News & Investment Opportunities
PRISM MarketView - Social Media (X)